PLATELET COUNT AS A RISK FACTOR FOR HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
(Abstract release date: 05/19/16)
EHA Library. Simonovic E. 06/09/16; 134939; PB2039
Dr. Evica Simonovic
Contributions
Contributions
Abstract
Abstract: PB2039
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. Hemorrhagic syndrome is a complication that occurs in about a quarter of patients with PV and even 60% of patients with ET. Bleeding can complicate the clinical course of IMF. It has been manifested in the form of petechiae and ecchymoses, or may be life-threatening as uncontrolled esophageal bleeding. It occurs due to ineffective megakaryocytopoiesis, retention of platelets in the enlarged spleen, qualitative platelet disorders, acquired deficiency of factors V and vWF, disseminated intravascular coagulation. The increased platelet count affects the adsorption of the larger von Willebrand multimers onto the platelet membrane, thus acting to eliminate them from circulation and degradation.
Aims
The aim of this study is to monitor the platelet count as a potential risk factor for occurrence of hemorrhagic complications in patients with chronic myeloproliferative neoplasms.
Methods
During the three-year period we monitored the occurrence of hemorrhagic complications and platelet count in 120 patients of both sexes aged between 27 and 86 years, being diagnosed with Ph-myeloproliferative neoplasms. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (51); 2. Group with essential thrombocythemia (ET) (24); 3. Group with idiopathic myelofibrosis (IMF) (20); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). We used methods of clinical, laboratory, endoscopy, ultrasound and CT scans.
Results
Platelet count ranged from 2,2-2134,5,1 x 109/L. The highest platelet count was recorded in the group of patients with ET and MPNs (p<0,001) and the lowest in the group of patients with the IMF (p<0,01). There was no statistical significant difference detected between the groups of patients with PV and MPNs with regard to platelet count. The highest percentage of hemorrhagic complications was found in the group of patients with ET and IMF (p<0,01) and then in the group with MPNs. Hemorrhagic complications have been more frequent in patients with platelet count below 10 x 109/L (p<0,05) and in patients with platelet counts over 1000 x 109/L (p<0,01). Life-threatening bleeding complications were the most common in patients with platelet count below 5 x 109/L and in patients with platelet count over 1500 x 109/L. Haemorrhage was the cause of mortality in 15% of patients with MPN.
Conclusion
The platelet count can be considered as a significant parameter for monitoring the risk of hemorrhagic complications in patients with myeloproliferative neoplasms, particularly with ET and IMF. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of hemorrhagic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Hemorrhage, Myeloproliferative disorder, Platelet
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. Hemorrhagic syndrome is a complication that occurs in about a quarter of patients with PV and even 60% of patients with ET. Bleeding can complicate the clinical course of IMF. It has been manifested in the form of petechiae and ecchymoses, or may be life-threatening as uncontrolled esophageal bleeding. It occurs due to ineffective megakaryocytopoiesis, retention of platelets in the enlarged spleen, qualitative platelet disorders, acquired deficiency of factors V and vWF, disseminated intravascular coagulation. The increased platelet count affects the adsorption of the larger von Willebrand multimers onto the platelet membrane, thus acting to eliminate them from circulation and degradation.
Aims
The aim of this study is to monitor the platelet count as a potential risk factor for occurrence of hemorrhagic complications in patients with chronic myeloproliferative neoplasms.
Methods
During the three-year period we monitored the occurrence of hemorrhagic complications and platelet count in 120 patients of both sexes aged between 27 and 86 years, being diagnosed with Ph-myeloproliferative neoplasms. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (51); 2. Group with essential thrombocythemia (ET) (24); 3. Group with idiopathic myelofibrosis (IMF) (20); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). We used methods of clinical, laboratory, endoscopy, ultrasound and CT scans.
Results
Platelet count ranged from 2,2-2134,5,1 x 109/L. The highest platelet count was recorded in the group of patients with ET and MPNs (p<0,001) and the lowest in the group of patients with the IMF (p<0,01). There was no statistical significant difference detected between the groups of patients with PV and MPNs with regard to platelet count. The highest percentage of hemorrhagic complications was found in the group of patients with ET and IMF (p<0,01) and then in the group with MPNs. Hemorrhagic complications have been more frequent in patients with platelet count below 10 x 109/L (p<0,05) and in patients with platelet counts over 1000 x 109/L (p<0,01). Life-threatening bleeding complications were the most common in patients with platelet count below 5 x 109/L and in patients with platelet count over 1500 x 109/L. Haemorrhage was the cause of mortality in 15% of patients with MPN.
Conclusion
The platelet count can be considered as a significant parameter for monitoring the risk of hemorrhagic complications in patients with myeloproliferative neoplasms, particularly with ET and IMF. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of hemorrhagic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Hemorrhage, Myeloproliferative disorder, Platelet
Abstract: PB2039
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. Hemorrhagic syndrome is a complication that occurs in about a quarter of patients with PV and even 60% of patients with ET. Bleeding can complicate the clinical course of IMF. It has been manifested in the form of petechiae and ecchymoses, or may be life-threatening as uncontrolled esophageal bleeding. It occurs due to ineffective megakaryocytopoiesis, retention of platelets in the enlarged spleen, qualitative platelet disorders, acquired deficiency of factors V and vWF, disseminated intravascular coagulation. The increased platelet count affects the adsorption of the larger von Willebrand multimers onto the platelet membrane, thus acting to eliminate them from circulation and degradation.
Aims
The aim of this study is to monitor the platelet count as a potential risk factor for occurrence of hemorrhagic complications in patients with chronic myeloproliferative neoplasms.
Methods
During the three-year period we monitored the occurrence of hemorrhagic complications and platelet count in 120 patients of both sexes aged between 27 and 86 years, being diagnosed with Ph-myeloproliferative neoplasms. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (51); 2. Group with essential thrombocythemia (ET) (24); 3. Group with idiopathic myelofibrosis (IMF) (20); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). We used methods of clinical, laboratory, endoscopy, ultrasound and CT scans.
Results
Platelet count ranged from 2,2-2134,5,1 x 109/L. The highest platelet count was recorded in the group of patients with ET and MPNs (p<0,001) and the lowest in the group of patients with the IMF (p<0,01). There was no statistical significant difference detected between the groups of patients with PV and MPNs with regard to platelet count. The highest percentage of hemorrhagic complications was found in the group of patients with ET and IMF (p<0,01) and then in the group with MPNs. Hemorrhagic complications have been more frequent in patients with platelet count below 10 x 109/L (p<0,05) and in patients with platelet counts over 1000 x 109/L (p<0,01). Life-threatening bleeding complications were the most common in patients with platelet count below 5 x 109/L and in patients with platelet count over 1500 x 109/L. Haemorrhage was the cause of mortality in 15% of patients with MPN.
Conclusion
The platelet count can be considered as a significant parameter for monitoring the risk of hemorrhagic complications in patients with myeloproliferative neoplasms, particularly with ET and IMF. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of hemorrhagic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Hemorrhage, Myeloproliferative disorder, Platelet
Type: Publication Only
Background
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell malignancies, characterized by overgrowth of one or more blood lines with normal or nearly normal maturing of those cells in the bone marrow and extramedullary hematopoietic organs. Hemorrhagic syndrome is a complication that occurs in about a quarter of patients with PV and even 60% of patients with ET. Bleeding can complicate the clinical course of IMF. It has been manifested in the form of petechiae and ecchymoses, or may be life-threatening as uncontrolled esophageal bleeding. It occurs due to ineffective megakaryocytopoiesis, retention of platelets in the enlarged spleen, qualitative platelet disorders, acquired deficiency of factors V and vWF, disseminated intravascular coagulation. The increased platelet count affects the adsorption of the larger von Willebrand multimers onto the platelet membrane, thus acting to eliminate them from circulation and degradation.
Aims
The aim of this study is to monitor the platelet count as a potential risk factor for occurrence of hemorrhagic complications in patients with chronic myeloproliferative neoplasms.
Methods
During the three-year period we monitored the occurrence of hemorrhagic complications and platelet count in 120 patients of both sexes aged between 27 and 86 years, being diagnosed with Ph-myeloproliferative neoplasms. Patients were classified into the following groups: 1. Group with the polycythemia vera (PV) (51); 2. Group with essential thrombocythemia (ET) (24); 3. Group with idiopathic myelofibrosis (IMF) (20); 4. Group with unclassified myeloproliferative neoplasm (MPNs) (25). We used methods of clinical, laboratory, endoscopy, ultrasound and CT scans.
Results
Platelet count ranged from 2,2-2134,5,1 x 109/L. The highest platelet count was recorded in the group of patients with ET and MPNs (p<0,001) and the lowest in the group of patients with the IMF (p<0,01). There was no statistical significant difference detected between the groups of patients with PV and MPNs with regard to platelet count. The highest percentage of hemorrhagic complications was found in the group of patients with ET and IMF (p<0,01) and then in the group with MPNs. Hemorrhagic complications have been more frequent in patients with platelet count below 10 x 109/L (p<0,05) and in patients with platelet counts over 1000 x 109/L (p<0,01). Life-threatening bleeding complications were the most common in patients with platelet count below 5 x 109/L and in patients with platelet count over 1500 x 109/L. Haemorrhage was the cause of mortality in 15% of patients with MPN.
Conclusion
The platelet count can be considered as a significant parameter for monitoring the risk of hemorrhagic complications in patients with myeloproliferative neoplasms, particularly with ET and IMF. Further follow-up and a larger number of subjects are needed. The follow-up of patients with unclassified myeloproliferative neoplasms has particularly important, which showed a high prevalence of hemorrhagic complications, and with the aim of their further differentiation.
Session topic: E-poster
Keyword(s): Hemorrhage, Myeloproliferative disorder, Platelet
{{ help_message }}
{{filter}}